Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Opeyemi A. Jegede"'
Autor:
Thomas Powles, Laurence Albiges, David F McDermott, Michael B Atkins, Toni K Choueiri, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Martin H Voss, Hans J Hammers, Chung-Han Lee, Robert J Motzer, Yoshihiko Tomita, Nizar M Tannir, Meredith M Regan, Charlene M Mantia, Lisa Rosenblatt, Opeyemi A Jegede
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Immunotherapy can be associated with prolonged disease control even after cessation of treatment without the need for further cancer-directed therapy. Treatment-related adverse events (TRAEs) can also persist after discontinuation of thera
Externí odkaz:
https://doaj.org/article/e929a9c890ec467cac7b04eb3f99fada
Autor:
Michael Hurwitz, Mark Stein, Jeffrey Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Meredith M Regan, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Paul J Catalano
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background As part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the cessation of immunotherapy and the start of subsequent therapy; both with and without toxicity.
Externí odkaz:
https://doaj.org/article/23ac543db705415f93126b90c7cd9853
Autor:
Michael Hurwitz, Elizabeth Plimack, Jeffrey Sosman, Sabina Signoretti, David F McDermott, Michael B Atkins, Naomi B Haas, Hans Hammers, Nicholas Schindler, Opeyemi A Jegede, Catherine J Wu, David Braun, Miya Hugaboom, Kelly Street, Neil Ruthen, Lena Wirth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8268242ef3d34b96ae74e8d3558065da
Autor:
Samir Gupta, Michael B Atkins, Meredith Regan, Neil J Shah, Jacob Zaemes, Opeyemi A Jegede, Shaked Lev Ari, Lauren Pascual, Natali Arias-Orozco, Brittany Sinclaire, Alexandra DellaPia, Rachel A Zemel, Yili Zhang, Adil Alaoui, Andrew Ip
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/543f662ef85345d892a18d4460b414d0
Autor:
Alessia Cimadamore, Michael Hurwitz, Mark Stein, Sabina Signoretti, Jeffrey A Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Thomas Denize, Catherine J Wu, David Braun, Paul J Catalano
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to
Externí odkaz:
https://doaj.org/article/f31aca68bfec4407896225ae6d30cdbd
Autor:
Michael B. Atkins, Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet A. Bilen, Mark Stein, Jeffrey A. Sosman, Robert Alter, Elizabeth R. Plimack, Moshe Ornstein, Michael Hurwitz, David J. Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J. Wu, David Braun, David Einstein, Paul J. Catalano, Hans Hammers
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(25)
PURPOSE To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive patients with clear cell renal cell carcinoma (ccRCC) and the efficacy of salvage
Autor:
Gordon J. Freeman, Sabina Signoretti, Antonio R. Arulanandam, David F. McDermott, Jie Zhu, Jo Soden, Ping Hua, Baogong Zhu, Maura Sticco-Ivins, Jean-Christophe Pignon, Paul J. Catalano, Opeyemi A. Jegede, Chun-Hau Chen, Samuel S. Freeman, Alyssa N. Klee, Kathleen M. Mahoney, Julie C. Konge, Abdulla Berjis, Rupal S. Bhatt
Blockade of the PD1 pathway is a broadly effective cancer therapy, but additional immune-inhibitory pathways contribute to tumor immune evasion. HERV–H LTR-associating 2 (HHLA2; also known as B7H5 and B7H7) is a member of the B7 family of immunoreg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::332b94b9c7b92f3f2b93b94a42d4aa9f
https://doi.org/10.1158/2326-6066.c.6550380.v1
https://doi.org/10.1158/2326-6066.c.6550380.v1
Autor:
Gordon J. Freeman, Sabina Signoretti, Antonio R. Arulanandam, David F. McDermott, Jie Zhu, Jo Soden, Ping Hua, Baogong Zhu, Maura Sticco-Ivins, Jean-Christophe Pignon, Paul J. Catalano, Opeyemi A. Jegede, Chun-Hau Chen, Samuel S. Freeman, Alyssa N. Klee, Kathleen M. Mahoney, Julie C. Konge, Abdulla Berjis, Rupal S. Bhatt
Supplementary Figures 1-7 and Supplementary Tables 1-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26775238f169d7ce6bf99bf38eb87c67
https://doi.org/10.1158/2326-6066.22543728
https://doi.org/10.1158/2326-6066.22543728
Autor:
Guru P. Sonpavde, Gurudatta Naik, Sumanta K. Pal, Heng Du, Mahsa Zarei, David A. Braun, Deborah L. Della Manna, Sarah Abou Alaiwi, Opeyemi A. Jegede, Elio Adib, Amin H. Nassar, Eddy S. Yang
Supplemtary figure and table legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83184cb810f279b8b2c4be7fc0fc6d6a
https://doi.org/10.1158/1535-7163.22522716.v1
https://doi.org/10.1158/1535-7163.22522716.v1
Autor:
Guru P. Sonpavde, Gurudatta Naik, Sumanta K. Pal, Heng Du, Mahsa Zarei, David A. Braun, Deborah L. Della Manna, Sarah Abou Alaiwi, Opeyemi A. Jegede, Elio Adib, Amin H. Nassar, Eddy S. Yang
CONSORT diagram for the phase I/II trial of everolimus with and without BNC105P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019cfb54c40416555ee49dc3e65f3d51
https://doi.org/10.1158/1535-7163.22522713.v1
https://doi.org/10.1158/1535-7163.22522713.v1